A detailed history of E Fund Management Co., Ltd. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 16,419 shares of NTLA stock, worth $199,983. This represents 0.02% of its overall portfolio holdings.

Number of Shares
16,419
Previous 12,665 29.64%
Holding current value
$199,983
Previous $283,000 19.08%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$19.72 - $27.36 $74,028 - $102,709
3,754 Added 29.64%
16,419 $337,000
Q2 2024

Aug 12, 2024

SELL
$20.02 - $27.22 $35,935 - $48,859
-1,795 Reduced 12.41%
12,665 $283,000
Q1 2024

May 13, 2024

SELL
$23.82 - $32.8 $49,807 - $68,584
-2,091 Reduced 12.63%
14,460 $397,000
Q4 2023

Feb 06, 2024

BUY
$23.16 - $32.34 $103,664 - $144,753
4,476 Added 37.07%
16,551 $504,000
Q3 2023

Nov 13, 2023

BUY
$31.62 - $45.78 $55,176 - $79,886
1,745 Added 16.89%
12,075 $382,000
Q2 2023

Aug 11, 2023

SELL
$34.58 - $46.03 $15,630 - $20,805
-452 Reduced 4.19%
10,330 $421,000
Q1 2023

May 11, 2023

SELL
$33.3 - $44.82 $10,689 - $14,387
-321 Reduced 2.89%
10,782 $402,000
Q4 2022

Feb 14, 2023

BUY
$33.21 - $62.69 $123,209 - $232,579
3,710 Added 50.18%
11,103 $387,000
Q3 2022

Nov 14, 2022

SELL
$53.92 - $71.7 $157,554 - $209,507
-2,922 Reduced 28.33%
7,393 $414,000
Q2 2022

Aug 15, 2022

BUY
$38.49 - $76.21 $228,553 - $452,534
5,938 Added 135.66%
10,315 $534,000
Q1 2022

May 12, 2022

BUY
$58.27 - $118.99 $131,748 - $269,036
2,261 Added 106.85%
4,377 $318,000
Q1 2021

May 12, 2021

BUY
$46.59 - $83.68 $98,584 - $177,066
2,116 New
2,116 $169,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $926M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.